PMID- 16445573
OWN - NLM
STAT- MEDLINE
DCOM- 20060317
LR  - 20131121
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 32
IP  - 12
DP  - 2005 Dec
TI  - Feitai, a Chinese herbal medicine, reduces transforming growth factor-beta1 and 
      monocyte chemoattractant protein-1 expression in bleomycin-induced lung fibrosis 
      in mice.
PG  - 1071-7
AB  - Feitai, a Chinese medicine formulation, has been shown to protect against lung 
      fibrosis induced by bleomycin (BLM). In the present study, we investigated the 
      effect of Feitai on transforming growth factor (TGF)-beta1 and monocyte 
      chemoattractant protein-1 (MCP-1), which play important roles in the pathogenesis 
      of BLM-induced lung fibrosis. The results demonstrated that Feitai could 
      significantly attenuate BLM-induced acute lung inflammation and subsequent lung 
      fibrosis. Meanwhile, the expression of MCP-1 and TGF-beta1 mRNA in the lungs 
      increased in the BLM-treated group compared with the saline-instilled control 
      group and Feitai treatment significantly decreased cytokine expression in 
      BLM-treated mice. In addition, Feitai diminished the accumulation of MCP-1- and 
      TGF-beta1-positive cells in lung tissues at the time of peak mRNA levels. In 
      summary, the results of the present study indicate that treatment with Feitai 
      ameliorates BLM-induced lung fibrosis, at least in part via the inhibition of 
      MCP-1 and TGF-beta1 expression.
FAU - Shen, Yun
AU  - Shen Y
AD  - Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 
      Shanghai, PR China. shenyun@sibs.ac.cn
FAU - Zhao, Hao-Long
AU  - Zhao HL
FAU - Du, Juan
AU  - Du J
FAU - Li, Yu-Ting
AU  - Li YT
FAU - Tan, Fang
AU  - Tan F
FAU - Huang, Cheng-Gang
AU  - Huang CG
FAU - Pei, Gang
AU  - Pei G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Feitai)
RN  - 0 (Tgfb1 protein, mouse)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 11056-06-7 (Bleomycin)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - RMB44WO89X (Hydroxyproline)
SB  - IM
MH  - Animals
MH  - *Anti-Bacterial Agents
MH  - *Bleomycin
MH  - Cell Differentiation/drug effects
MH  - Chemokine CCL2/*biosynthesis
MH  - Drugs, Chinese Herbal/*pharmacology/therapeutic use
MH  - Female
MH  - Fibroblasts/drug effects
MH  - Hydroxyproline/metabolism
MH  - Immunohistochemistry
MH  - Lung/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Peroxidase/metabolism
MH  - Pulmonary Fibrosis/*chemically induced/*metabolism/prevention & control
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transforming Growth Factor beta/*biosynthesis
MH  - Transforming Growth Factor beta1
EDAT- 2006/02/01 09:00
MHDA- 2006/03/18 09:00
CRDT- 2006/02/01 09:00
PHST- 2006/02/01 09:00 [pubmed]
PHST- 2006/03/18 09:00 [medline]
PHST- 2006/02/01 09:00 [entrez]
AID - CEP4314 [pii]
AID - 10.1111/j.1440-1681.2005.04314.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1071-7. doi: 
      10.1111/j.1440-1681.2005.04314.x.